Segall Bryant & Hamill LLC Lowers Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Segall Bryant & Hamill LLC decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 8.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,946 shares of the company's stock after selling 1,856 shares during the quarter. Segall Bryant & Hamill LLC's holdings in IDEXX Laboratories were worth $7,956,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Victory Capital Management Inc. boosted its holdings in IDEXX Laboratories by 4.1% during the 1st quarter. Victory Capital Management Inc. now owns 180,165 shares of the company's stock valued at $75,660,000 after acquiring an additional 7,034 shares during the period. Larson Financial Group LLC raised its position in IDEXX Laboratories by 10.0% during the 1st quarter. Larson Financial Group LLC now owns 670 shares of the company's stock valued at $281,000 after purchasing an additional 61 shares in the last quarter. Sage Mountain Advisors LLC raised its position in IDEXX Laboratories by 3.8% during the 1st quarter. Sage Mountain Advisors LLC now owns 635 shares of the company's stock valued at $267,000 after purchasing an additional 23 shares in the last quarter. Wealthfront Advisers LLC raised its position in IDEXX Laboratories by 7.0% during the 1st quarter. Wealthfront Advisers LLC now owns 6,546 shares of the company's stock valued at $2,749,000 after purchasing an additional 428 shares in the last quarter. Finally, TimesSquare Capital Management LLC raised its position in IDEXX Laboratories by 2.2% during the 1st quarter. TimesSquare Capital Management LLC now owns 197,746 shares of the company's stock valued at $83,043,000 after purchasing an additional 4,230 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Down 0.8%

NASDAQ:IDXX traded down $4.10 during mid-day trading on Friday, hitting $514.61. 329,531 shares of the company's stock traded hands, compared to its average volume of 642,698. The company has a fifty day moving average of $523.58 and a 200 day moving average of $463.04. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $549.52. The company has a market capitalization of $41.38 billion, a P/E ratio of 47.56, a P/E/G ratio of 3.74 and a beta of 1.54. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.16.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.03. The business had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The company's quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.71 EPS. On average, analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Stifel Nicolaus lifted their target price on IDEXX Laboratories from $510.00 to $540.00 and gave the company a "hold" rating in a research report on Wednesday, July 2nd. Jefferies Financial Group initiated coverage on IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price target for the company. Morgan Stanley boosted their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Wall Street Zen raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Saturday, July 12th. Finally, Leerink Partners boosted their price target on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and an average price target of $560.33.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the business's stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the sale, the director owned 1,801 shares in the company, valued at approximately $922,724.34. The trade was a 41.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.98% of the company's stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.